Vertex Pharmaceuticals Inc
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals AIPR&D by Year
AIPR&D — Other in-license & collaboration upfront/milestone payments ($M) ($M)
Vertex Pharmaceuticals AIPR&D: $146M in FY2025, up 52.8% from a year earlier.
Latest, FY2025
146
Period ended Dec 31, 2025
Change on a year earlier
+52.8%
95.2 in FY2024
History
5 years
Since FY2021
Sources
3
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-K Note (Collaborative Arrangements — AIPR&D Breakdown).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | AIPR&D — Other in-license & collaboration upfront/milestone payments ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 146 | +52.8% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 95.2 | -16.9% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 115 | +106.3% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 55.5 | -59.9% | Form 10-K (filed 2025-02-13) ↗ |
| FY2021 | Dec 31, 2021 | 138 | – | Form 10-K (filed 2024-02-15) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals AIPR&D ($M), annual FY2021–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/other-inlicense-aiprd
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.